A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...

According to GlobalData, Phase III drugs for Subacute Cutaneous Lupus Erythematosus (SCLE ... It is a fully human monoclonal antibody. It targets IFN-alpha receptor subunit 1 (IFNAR1). The drug ...

Research Center for Environmental Quality Management, Graduate School of Engineering, Kyoto University, Otsu, Shiga 520-0811, Japan Key Laboratory of Industrial Ecology and Environmental Engineering ...

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related ...

Davis R Ingram; Lloye M Dillon; Dina Chelouche Lev; Alexander Lazar; Elizabeth G Demicco; Burton L Eisenberg; Todd W Miller ...

These evasion strategies start at early stages of infection by hijacking immune receptors to mitigate the cellular response. In this study, we examined whether Leishmania uses the Fc receptor ...